Login to Your Account

Affimed's $20M Series D Funds Its Bispecific Antibody R&D

By Nuala Moran
Staff Writer

Wednesday, October 10, 2012
LONDON – Affimed Therapeutics AG closed a €15.5 million (US$20 million) Series D funding round, enabling it to advance clinical development of its two leading second-generation TandAb bispecific antibodies.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription